Creso Pharma (ASX:CPH) welcomes the Royal Commission and clinical studies on psilocybin, page-4

The game for CPH has changed ten folds in the last 8 months with POs after POs, deals after deals, acquisitions, growth of 491% YoY which is reflected in the share price rocket from 2.4 cents to 47.5 cents.

CPH is not the company it was 12 months ago.

If you listened to the self proclaimed down ramper here 8 months ago and sold out early and missed out on 1900% increase in the share price, you are yourself to blame.

The same boring movie is on repeat from the the non holders down ramping brigade.

DYOR.